US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

MediciNova, Inc. - Common Stock (NQ:MNOV)

1.780 +0.150 (+9.20%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediciNova, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
From MediciNova, Inc.
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
We're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today! 
Via InvestorPlace
News headline image
MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
From MediciNova, Inc.
Via GlobeNewswire
Medicinova Inc. (NASDAQ: MNOV) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates ↗
 
Via Benzinga
News headline image
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Posts Promising Data From COVID-19 Treatment Candidate ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder
From MediciNova, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma
Preliminary results will be presented at the 20th Annual World Congress of the Society for Brain Mapping and Therapeutics 
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)
MN-166 (ibudilast) parenteral formulation showed a favorable safety and tolerability profile in healthy volunteers 
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse
From MediciNova, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 297 companies achieved new lows for the year. 
Via Benzinga
News headline image
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea
From MediciNova, Inc.
Via GlobeNewswire
News headline image
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary ↗
 
Via Benzinga
News headline image
MediciNova Commences Mid-Stage Non-alcoholic Fatty Liver Disease Study ↗
MediciNova (NASDAQ: MNOV) initiated a Phase 2 clinical trial to evaluate MN-001 (tipelukast) for the treatment of patients with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus... 
Via Benzinga
News headline image
MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
From MediciNova, Inc.
Via GlobeNewswire
News headline image
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
83 Biggest Movers From Yesterday ↗
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly... 
Via Benzinga
News headline image
50 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback. 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >